Intravenous immunoglobulin treatment in multiple sclerosis: Effect on relapses

Neurology

Volumn 50, Issue 2, 1998, Pages 398-402

  Achiron, A ^a   Gabbay, U ^b   Gilad, R ^c   Hassin Baer, S ^a   Barak, Y ^d   Gornish, M ^e   Elizur, A ^d   Goldhammer, Y ^a   Sarova Pinhas, I ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

^d ABARBANEL MENTAL HEALTH CENTER   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; TREATMENT OUTCOME;

EID: 0031911494     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.2.398     Document Type: Article

References (34)

1. Poser S, Wilkstrom J, Bauer HJ. Clinical data and identification of special forms of multiple sclerosis with a standardised documentation system. J Neurol Sci 1979;40:159-168.
2. Patzold, U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out on 102 MS patients from 1976-80. Acta Neurol Scand 1982;65:248-266.
3. Dijkstra CD, Polman CH, Berkenbosch F. Multiple sclerosis: some possible therapeutic opportunities. Trends Pharmacol Sci 1993;14:124-129.
4. Carter JL, Hafler DA, Dawson DM, et al. Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988;38(suppl 2):9-14.
5. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:180-183.
6. Cook SD, Devereux C, Tvoiano R, et al. Effect of total lymphocyte irradiation in chronic progressive multiple sclerosis. Lancet 1986;1:1405-1409.
7. Dommasch D. Comparative clinical trial of cyclosporine in multiple sclerosis: the pros. Neurology 1988;38(suppl):28-29.
8. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Semin Hematol 1988;25:140-158.
9. Edan G, Landgraf F. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 1994;57(suppl):55-56.
10. Cook SD, Troiano R, Rohowsky-Kochin C, et al. Intravenous gammaglobulin in progressive MS. Acta Neurol 1992;86:171-175.
11. van Engelen BG, Hommes OR, Pinckers A, et al. Improved vision after intravenous immunoglobulin in stable demyelinating optin neuritis. Ann Neurol 1992;32:834-835.
12. Noseworthy JH, Rodriguez M, An KN, et al. IVIg treatment in multiple sclerosis: pilot study results and design of placebo-controlled, double-blind clinical trial. Ann Neurol 1994;A:325.
13. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of high-dose intravenous immunoglobulins in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:1233-1236.
14. Achiron A, Gilad R, Margalit R, et al. Intravenous gamma-globulin treatment in multiple sclerosis and experimental autoimmune diseases: delineation of usage and mode of action. J Neurol Neurosurg Psychiatry 1994;57(suppl):57-61.
15. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
17. Achiron A, Barak Y, Goren M, et al. Intravenous immunoglobulin in multiple sclerosis: clinical and neuroradiologic results and implications for possible mechanisms of action. Clin Exp Immunol 1996;104(suppl 1):67-70.
18. Fisher RA. Statistical methods for research workers, 5th ed. Edinburgh: Oliver and Boyd, 1934.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. Brain 1980;103:281-300.
21. Hermitte F, Morteau R, Gazengel J, Dordain J, Deloche G. The frequency of relapse in multiple sclerosis: a study based on 245 cases. J Neurol 1975;205:47-59.
22. van Oosten BW, Truyen L, Barkhof F, Polman CH. Multiple sclerosis therapy. Drugs 1995;49:200-212.
23. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-593.
24. Thompson AJ, Miller D, Youl F, et al. Serial gadolinium enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
25. Glass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-67.
26. Paty DW, Li DKD, Oger JJF, et al. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol 1994;36:895-896.
27. Sandor M, Houlden BW, Bluestone JA, et al. In vitro and in vivo activation of murine τ/T cells induce the expression of IgA, IgM, and IgC Fc receptors. J Immunol 1992;148:2363-2369.
28. Nyland H, Nilsen R. Localization of Fcg receptors in the human central nervous system. Acta Pathol Microbiol Immunol Scand 1982;90:217-221.
29. Ulvetad E, Williams K, Vedeler C, et al. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 1994;121:125-131.
30. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
31. Andersson U, Bjork L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21-42.
32. Rodriguez M. Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990;27:12-17.
33. Wurster U, Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 1994;57(suppl):21-35.
34. Achiron A, Rotstein Z, Noy S, et al. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis - a pilot study. J Neurol 1996;243:25-28.